249 related articles for article (PubMed ID: 15636503)
1. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
Spake A
US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
[No Abstract] [Full Text] [Related]
2. The FDA and congress: differing agendas?
Lipman AG
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
[No Abstract] [Full Text] [Related]
3. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
Schweitzer SO
N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
[No Abstract] [Full Text] [Related]
4. Playing "kick the FDA"--risk-free to players but hazardous to public health.
Wood AJ
N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
[No Abstract] [Full Text] [Related]
5. Criminal conviction for distribution of a drug not approved by the FDA.
Brushwood DB
Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
[No Abstract] [Full Text] [Related]
6. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
Niedelman SM
Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
[No Abstract] [Full Text] [Related]
7. FDA, industry collaborate to strengthen painkiller restrictions.
Sipkoff M
Manag Care; 2009 Apr; 18(4):10-1. PubMed ID: 19472560
[No Abstract] [Full Text] [Related]
8. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
Hubbard WK
Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
[No Abstract] [Full Text] [Related]
9. Maker of growth hormone feels long arm of law.
Nordenberg T
FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
[No Abstract] [Full Text] [Related]
10. The goals of FDA regulation and the challenges of meeting them.
Tyler RS
Health Matrix Clevel; 2013; 22(2):423-31. PubMed ID: 23668096
[No Abstract] [Full Text] [Related]
11. The danger of imperfect regulation: OxyContin use in the United States and Canada.
Lexchin J; Kohler JC
Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
[TBL] [Abstract][Full Text] [Related]
12. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
13. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
Teufel AT
J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
[No Abstract] [Full Text] [Related]
14. A bitter pill for one Merck critic.
McLean B
Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
[No Abstract] [Full Text] [Related]
15. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
16. Rules for evaluating biosimilars put applicants through hoops.
Morrow T
Manag Care; 2012 Mar; 21(3):56-7. PubMed ID: 22471166
[No Abstract] [Full Text] [Related]
17. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
Cooper DE
Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
[No Abstract] [Full Text] [Related]
18. Regulatory science and the role of the regulator in biomedical innovation.
Honig PK; Huang SM
Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
[No Abstract] [Full Text] [Related]
19. Pharmaceutical product integrity: can the FDA assure quality?
Bernstein I
Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168
[No Abstract] [Full Text] [Related]
20. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
